Trajan Group Acquires Axel Semrau GmbH

Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has completed the acquisition of Axel Semrau GmbH & Co. KG and Semrau Immobilien GmbH & Co. KG, the private business and properties of “Axel Semrau” based in Sprockhövel, Germany for €14.75 million and €2.25 million respectively. Adjustments, including accumulated undistributed profits total €2.85 million in favour of the sellers, to be paid by Trajan following Closing. Trajan is funding its current acquisition activities through a combination of cash and debt.

Axel Semrau employs just over 50 staff in Europe and develops and manufactures laboratory automation and chromatography software and detection systems. The company reported FY 21 (year ended Sept ’21) revenues of €14.9 million, and EBITDA of €1.46 million (normalized EBITDA of €1.67 million), unaudited.

Stephen Tomisich, Chief Executive Officer and Managing Director, Trajan stated, “We welcome the Axel Semrau team to the Trajan group. Trajan’s automation business and Axel Semrau have worked in close cooperation for several years and so we enter this new stage with a working relationship already well established. Axel Semrau owns and develops the CHRONOS intelligent sequencing software platform upon which Trajan’s automated workflows are built. We intend to further invest in CHRONOS in line with Trajan’s goal to simplify and automate complex analytical workflows.”

“Further, Axel Semrau’s automation business is highly synergistic with our own; both in terms of application areas and geographical coverage. Axel Semrau’s presence in chromatography and portable/on line gas detection also align with Trajan’s general direction.”

The two Managing Directors at Axel Semrau, Frank Sasse and Andreas Bruchmann and all other employees will continue in their current roles as part of the Trajan group. Dr Bruchmann commented “We welcome the opportunity to become part of the Trajan team. We have known Trajan for some time and find that our goals and values are aligned. We also see the intention of ongoing investment to drive growth in our business and capabilities.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”